Research Summary

Statins Cut Mortality, Major Cardiovascular Events in UK Adults with Type 2 Diabetes Across Risk Levels

Edited by:
Kate Young

Key Highlights

  • In a UK population cohort with type 2 diabetes, statin initiation was associated with reduced all-cause mortality and major cardiovascular events compared with non-use.
  • Benefits were observed even among individuals classified as low cardiovascular risk based on predicted 10-year risk.
  • A small increase in myopathy was noted in one risk stratum, with no significant liver safety signal.
  • Findings support reconsideration of risk-based thresholds for primary prevention statin therapy in type 2 diabetes.

In a real-world cohort analysis published in Annals of Internal Medicine, researchers from the University of Hong Kong and collaborators reported that statin therapy initiation for primary prevention was linked with statistically significant reductions in all-cause mortality and major atherosclerotic cardiovascular events among adults with type 2 diabetes, including those with lower estimated cardiovascular risk.

To evaluate the association between statin use and clinical outcomes, investigators conducted a retrospective cohort study using the IQVIA Medical Research Data (IMRD-UK) database, which includes primary care records representative of the UK population. Eligible participants were adults aged 25 to 84 years with type 2 diabetes and no documented history of serious cardiovascular or liver disease at baseline. Statin initiators were compared with non-initiators across strata of predicted 10-year cardiovascular disease (CVD) risk. Follow-up extended up to 10 years for mortality and major cardiovascular outcomes.

Study Findings

Across all risk groups, statin therapy was associated with lower hazards of all-cause death and major CVD events compared with non-use, even among individuals whose predicted 10-year CVD risk placed them in lower-risk categories. While a very small increase in clinically recognized myopathy emerged in one risk stratum, analyses did not detect a meaningful increase in liver injury associated with statin initiation. The consistency of benefit across risk levels suggests broad protective effects of statins beyond traditional risk threshold cutpoints.

Clinical Implications

The study authors found that even patients with lower predicted short-term CVD risk experienced reductions in mortality and major cardiovascular events when initiating statins, a group for whom guideline recommendations can be less definitive. While a small uptick in myopathy was observed in the moderate-risk group, there was no associated increased risk for liver dysfunction in any stratum.

The authors noted limitations including unmeasured confounding and under-detection of some hospitalization outcomes.

Expert Commentary

“Statin use in T2DM for primary prevention was associated with reductions in all-cause mortality and major CVD across the full spectrum of predicted cardiovascular risk,” the researchers concluded.

References:

  1. Wan EYF, et al. Statins significantly reduce mortality risk for adults with diabetes, regardless of cardiovascular risk. Ann Intern Med. Published online December 29, 2025. doi:10.7326/ANNALS-25-00662.
  2. Satins significantly reduce mortality risk for adults with diabetes, regardless of cardiovascular risk. https://www.eurekalert.org/news-releases/1110823. Published Dec. 29, 2025. Accessed Jan. 5, 2025.